Join Growin Stock Community!

Kalaris therapeutics incKLRS.US Overview

US StockHealthcare
(No presentation for KLRS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

KLRS AI Insights

KLRS Overall Performance

KLRS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

KLRS Recent Performance

0.67%

Kalaris therapeutics inc

0.05%

Avg of Sector

-0.31%

S&P500

KLRS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

KLRS Key Information

KLRS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

KLRS Profile

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Price of KLRS

KLRS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

KLRS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.76
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
4.61
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.76
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
4.61
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is KLRS's latest earnings report released?

    The most recent financial report for Kalaris therapeutics inc (KLRS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating KLRS's short-term business performance and financial health. For the latest updates on KLRS's earnings releases, visit this page regularly.

  • How much debt does KLRS have?

    As of the end of the reporting period, Kalaris therapeutics inc (KLRS) had total debt of 1.55M, with a debt ratio of 0.02. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does KLRS have?

    At the end of the period, Kalaris therapeutics inc (KLRS) held Total Cash and Cash Equivalents of 42.89M, accounting for 0.53 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is KLRS's EPS continuing to grow?

    According to the past four quarterly reports, Kalaris therapeutics inc (KLRS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.64. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of KLRS?

    Kalaris therapeutics inc (KLRS)'s Free Cash Flow (FCF) for the period is -11.33M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 34.29% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of KLRS?

    The latest valuation data shows Kalaris therapeutics inc (KLRS) has a Price-To-Earnings (PE) ratio of -1.79 and a Price/Earnings-To-Growth (PEG) ratio of -0.46. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.